Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Inhibition of NSD2 in t(4;14) myeloma induces changes in mitochondrial priming

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJonathan C. PattonRORebecca OwensVGVikas A. Gupta

Discussion

Loading...

Member takes

Overview

Inhibition of NSD2 increases cytochrome c loss and alters BCL2 family priming in t(4;14) myeloma cells, suggesting therapeutic potential.

Key Points

  • Inhibition of NSD2 led to altered mitochondrial priming, with specific cell line responses observed in t(4;14) myeloma.
  • KMS34 showed a 10-12% delta priming increase with BAD peptide, linking BCL-XL and BCL2 sensitivity.
  • Dynamic BH3 profiling techniques helped reveal variability in mitochondrial priming across different myeloma cell lines.
  • These insights point to a need for tailored approaches in treating patients with t(4;14) myeloma based on priming status.

Cite This Study

Patton et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236de89https://doi.org/10.1182/blood-2025-2177
View Full Paper
Ask AI
Bookmark
Share